Tim-3及Galectin-9的表达与肿瘤T细胞免疫在鼻咽癌中的临床意义

被引:0
|
作者
苏赓 [1 ]
王启俊 [2 ]
邹昂儒 [3 ]
杜杨君 [1 ]
庄劲 [4 ]
吴可嘉 [1 ]
机构
[1] 广西壮族自治区民族医院病理科
[2] 广西壮族自治区民族医院耳鼻喉科
[3] 广西壮族自治区民族医院体检科
[4] 广西壮族自治区民族医院肿瘤科
关键词
Tim-3; Galectin-9; 肿瘤免疫; 鼻咽癌;
D O I
暂无
中图分类号
R739.63 [咽肿瘤];
学科分类号
摘要
目的 探讨T细胞免疫球蛋白黏蛋白分子(Tim-3)及半乳糖凝集素-9(Galectin-9)的表达与肿瘤T细胞免疫在鼻咽癌中的临床意义。方法 在癌症基因组图谱计划(The Cancer Genome Atlas, TCGA)数据库中查找Tim-3在各种肿瘤组织中的表达情况,选取与鼻咽癌患者免疫密切相关的基因Tim-3及其配体Galectin-9作为研究基因;收集2018年3月~2022年3月广西壮族自治区民族医院收治的65例鼻咽癌患者的肿瘤组织、同期65例鼻咽部炎性标本组织及对应鼻咽癌患者放疗前后应用免疫细胞病理芯片技术检测的外周血T细胞亚群变化的数据,并做随访观察。结果 生物信息学分析TCGA数据库中鼻咽癌的测序数据,结果显示,Tim-3在大部分肿瘤组织中呈高表达,在鼻咽癌组织中较癌旁正常组织表达水平显著上调,Tim-3及其配体Galectin-9在癌组织中的表达呈正相关;免疫组化结果显示,鼻咽癌组织中Tim-3和Galectin-9的表达水平均显著高于鼻咽部炎性组织(P<0.05);鼻咽癌组织中Tim-3和Galectin-9高表达与淋巴结受累(P<0.05)以及更晚的TNM分期(P<0.05)紧密相关;Tim-3和Galectin-9的表达水平与患者年龄、性别及EB病毒感染等因素无关(P>0.05);Tim-3和Galectin-9在鼻咽癌中的表达呈正相关(r=0.313,P=0.011);随访发现,Tim-3和Galectin-9的高表达可能与鼻咽癌的不良预后相关;鼻咽癌患者放疗前3天和放疗后7天的T淋巴细胞亚群检测显示,CD4+、CD4+/CD8+较放疗前显著下降(P<0.05),CD3+与CD8+变化差异无统计学意义(P>0.05);Tim-3和Galectin-9蛋白阳性组患者放疗敏感度明显高于于Tim-3和Galectin-9阴性组(P<0.05)。结论 Tim-3/Galectin-9信号通路在鼻咽癌发生、发展和转移中起重要作用,T细胞免疫在鼻咽癌治疗中发挥重要作用。联合检测鼻咽癌组织中Tim-3和Galectin-9及T细胞亚群的变化可能为临床评估肿瘤监测病情及肿瘤免疫治疗提供新参数。
引用
收藏
页码:182 / 187
页数:6
相关论文
共 10 条
  • [1] Activated Tim-3/Galectin-9 participated in the development of multiple myeloma by negatively regulating CD4 T cells
    Zhang, Rui
    Chen, Shuang
    Luo, Tingting
    Guo, Sha
    Qu, Jianhua
    [J]. HEMATOLOGY, 2024, 29 (01)
  • [2] Combined TIM-3 and PD-1 blockade restrains hepatocellular carcinoma development by facilitating CD4+ and CD8+ T cell-mediated antitumor immune responses
    Zhang, Xu-Sheng
    Zhou, Hong-Cai
    Wei, Peng
    Chen, Long
    Ma, Wei-Hu
    Ding, Lin
    Liang, Shi-Cai
    Chen, Ben-Dong
    [J]. WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2023, 15 (12)
  • [3] Recurrent/Metastatic Nasopharyngeal Carcinoma Treatment from Present to Future: Where Are We and Where Are We Heading?.[J].JuarezVignon Whaley Juan Jose;Afkhami Michelle;Onyshchenko Mykola;Massarelli Erminia;Sampath Sagus;Amini Arya;Bell Diana;Villaflor Victoria M.Current treatment options in oncology.2023, 9
  • [4] The tumor immune microenvironment of nasopharyngeal carcinoma after gemcitabine plus cisplatin treatment
    Lv, Jiawei
    Wei, Yuan
    Yin, Jian-Hua
    Chen, Yu-Pei
    Zhou, Guan-Qun
    Wei, Chen
    Liang, Xiao-Yu
    Zhang, Yuan
    Zhang, Cui-Juan
    He, Shi-Wei
    He, Qing-Mei
    Huang, Zhuo-Li
    Guan, Jia-Li
    Shen, Jia-Yi
    Li, Xiao-Min
    Li, Jun-Yan
    Li, Wen-Fei
    Tang, Ling-Long
    Mao, Yan-Ping
    Guo, Rui
    Sun, Rui
    Zheng, Yu-Hui
    Zhou, Wen-Wen
    Xiong, Ke-Xu
    Wang, Si-Qi
    Jin, Xin
    Liu, Na
    Li, Gui-Bo
    Kuang, Dong-Ming
    Sun, Ying
    Ma, Jun
    [J]. NATURE MEDICINE, 2023, 29 (06) : 1424 - +
  • [5] Significance of TIM-3 Expression in Resected Esophageal Squamous Cell Carcinoma
    Zhao, Yuhuan
    Chen, Donglai
    Wang, Wenjia
    Zhao, Ting
    Wen, Junmiao
    Zhang, Fuquan
    Duan, Shanzhou
    Chen, Chang
    Sang, Yonghua
    Zhang, Yongsheng
    Chen, Yongbing
    [J]. ANNALS OF THORACIC SURGERY, 2020, 109 (05) : 1551 - 1557
  • [6] Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation?
    Masterson, Liam
    Howard, James
    Gonzalez-Cruz, Jazmina
    Jackson, Christopher
    Barnett, Catherine
    Overton, Lewis
    Liu, Howard
    Ladwa, Rahul
    Simpson, Fiona
    McGrath, Margie
    Wallwork, Ben
    Jones, Terry
    Ottensmeier, Christian
    Chua, Melvin L. K.
    Perry, Chris
    Khanna, Rajiv
    Panizza, Benedict
    Porceddu, Sandro
    Lechner, Matt
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2020, 146 (08) : 2305 - 2314
  • [7] TIM-3 Participates in the Invasion and Metastasis of Nasopharyngeal Carcinoma via SMAD7/SMAD2/SNAIL1 Axis-Mediated Epithelial-Mesenchymal Transition..[J].Xiao Yangyang;Qing Jilin;Li Baoxuan;Chen Liuyan;Nong Shengzhou;Yang Wenhui;Tang Xiaogang;Chen Zhizhong.OncoTargets and therapy.2020,
  • [8] Crosstalk between histone modification and DNA methylation orchestrates the epigenetic regulation of the costimulatory factors; Tim‑3 and galectin‑9; in cervical cancer..[J].Zhang Li;Tian Sijuan;Pei Meili;Zhao Minyi;Wang Li;Jiang Yifan;Yang Ting;Zhao Juan;Song Lihua;Yang Xiaofeng.Oncology reports.2019, 6
  • [9] Possible therapeutic applicability of galectin-9 in cutaneous T-cell lymphoma
    Nakajima, Rina
    Miyagaki, Tomomitsu
    Kamijo, Hiroaki
    Oka, Tomonori
    Shishido-Takahashi, Naomi
    Suga, Hiraku
    Sugaya, Makoto
    Sato, Shinichi
    [J]. JOURNAL OF DERMATOLOGICAL SCIENCE, 2019, 96 (03) : 134 - 142
  • [10] 中国临床肿瘤学会(CSCO)头颈部肿瘤诊疗指南.[M].中国临床肿瘤学会指南工作委员会.人民卫生出版社.2024,